Ribomic Inc. (TYO:4591)

Japan flag Japan · Delayed Price · Currency is JPY
74.00
-1.00 (-1.33%)
Aug 6, 2026, 1:33 PM JST
Market Cap4.24B -5.8%
Revenue (ttm)3.00M +50.0%
Net Income-1.15B
EPS-23.06
Shares Out 56.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume340,000
Open73.00
Previous Close75.00
Day's Range73.00 - 76.00
52-Week Range57.00 - 127.00
Beta0.19
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Ribomic

Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glauco... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4591
Full Company Profile

Financial Performance

In fiscal year 2026, Ribomic's revenue was 3.00 million, an increase of 50.00% compared to the previous year's 2.00 million. Losses were -1.15 billion, 12.5% more than in 2025.

Financial Statements